Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 0.49 |
| ▸ | CYP46A1 | Q9Y6A2 | 3/20 | 0.40 |
| ▸ | PTPRA | P18433 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069459 | 0.89 | RET (0.51) | RETCYP46A1PTPRALMNAGAA | |
| SCHEMBL20069464 | 0.87 | RET (0.49) | RETCYP46A1PTPRAALDH1A1SMN1; SMN2 | |
| SCHEMBL25502483 | 0.87 | RET (0.51) | RETCYP46A1PTPRALMNAGAA | |
| SCHEMBL21651944 | 0.82 | RET (0.44) | RETCYP46A1ALDH1A1 | |
| SCHEMBL20069623 | 0.79 | RET (0.49) | RETCYP46A1GAAHSD11B1KDM4E | |
| SCHEMBL20147912 | 0.76 | RET (0.50) | RETCYP46A1GAAHSD11B1KDM4E | |
| SCHEMBL22857003 | 0.74 | RET (0.49) | RETCYP46A1PTPRAALDH1A1SMN1; SMN2 | |
| SCHEMBL20069617 | 0.74 | RET (0.53) | RETLMNAHSD11B1KDM4EALDH1A1 | |
| SCHEMBL20158570 | 0.74 | RET (0.50) | RETCYP46A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20158569 | 0.74 | RET (0.51) | RETCYP46A1PTPRAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885CYP46A1 4055/4885PTPRA 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.